{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:24:45Z","timestamp":1788920685791,"version":"build-2803163510"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Respiratory syncytial virus (RSV) is a ubiquitous virus and the leading cause of pediatric hospitalization in the United States. Prevention strategies are key for reducing the burden of RSV. Several new agents aimed at preventing RSV in infants and children were FDA-approved in 2023, and many more are in the development pipeline. This review highlights new developments in RSV prevention in pediatric patients and the important safety considerations for clinical trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Two new preventive therapies were FDA approved in 2023; a maternal vaccine (Abrysvo) and a mAb (Beyfortus) have both demonstrated reduction in medically attended lower respiratory tract infections in infants and children. Evaluation of ongoing clinical trials demonstrates that the field is expanding further to include direct immunization of infants and children utilizing a variety of delivery modalities. While these developments present the optimistic prospect of RSV prevention in a range of ages, acute and long-term risks must be carefully evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Prevention of RSV is more accessible than ever, but careful consideration must be given to risks associated with new and developing prevention strategies. Rigor of clinical trials including longitudinal outcomes of agents in development and postmarketing surveillance of newly approved therapies will be of paramount importance to ensure long-term safety of new RSV prevention strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001336","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T10:02:15Z","timestamp":1706781735000},"page":"182-189","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Recent advances in the prevention of respiratory syncytial virus in pediatrics"],"prefix":"10.1097","volume":"36","author":[{"given":"Madeline A.","family":"Lipp","sequence":"first","affiliation":[{"name":"Center for Clinical Pharmaceutical Sciences"},{"name":"Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry M.","family":"Empey","sequence":"additional","affiliation":[{"name":"Center for Clinical Pharmaceutical Sciences"},{"name":"Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy"},{"name":"Department of Immunology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0140-6736(23)00811-5","article-title":"Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study","volume":"401","author":"Rosas-Salazar","year":"2023","journal-title":"Lancet"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/jiaa752","article-title":"Respiratory syncytial virus-associated hospitalization rates among US infants: a systematic review and meta-analysis","volume":"225","author":"McLaughlin","year":"2022","journal-title":"J Infect Dis"},{"issue":"(Suppl 2)","key":"R3-20250730","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1093\/infdis\/jiac172","article-title":"Cost of respiratory syncytial virus infections in US infants: systematic literature review and analysis","volume":"226","author":"Bowser","year":"2022","journal-title":"J Infect Dis"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"1004739","DOI":"10.3389\/fped.2022.1004739","article-title":"Risk factors associated with severe disease in respiratory syncytial virus infected children under 5\u200ayears of age","volume":"10","author":"Havdal","year":"2022","journal-title":"Front Pediatr"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"e20193611","DOI":"10.1542\/peds.2019-3611","article-title":"Respiratory syncytial virus-associated hospitalizations among young children: 2015\u20132016","volume":"146","author":"Rha","year":"2020","journal-title":"Pediatrics"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/jpids\/piz087","article-title":"Estimated burden of community-onset respiratory syncytial virus-associated hospitalizations among children aged <2 years in the United States","volume":"9","author":"Arriola","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S1473-3099(22)00291-2","article-title":"Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape","volume":"23","author":"Mazur","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"R9-20250730","first-page":"3","article-title":"Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease","volume":"372","author":"Collins","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13052-019-0704-0","article-title":"Respiratory Syncityal Virus A and B: three bronchiolitis seasons in a third level hospital in Italy","volume":"45","author":"Ciarlitto","year":"2019","journal-title":"Ital J Pediatr"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1743-422X-11-36","article-title":"Evaluation of respiratory syncytial virus group A and B genotypes among nosocomial and community-acquired pediatric infections in Southern Brazil","volume":"11","author":"de-Paris","year":"2014","journal-title":"Virol J"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"5625","DOI":"10.1073\/pnas.84.16.5625","article-title":"The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins","volume":"84","author":"Johnson","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1128\/JVI.01080-07","article-title":"Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity","volume":"82","author":"Loo","year":"2008","journal-title":"J Virol"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1128\/jvi.62.11.4232-4238.1988","article-title":"Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies","volume":"62","author":"Anderson","year":"1988","journal-title":"J Virol"},{"key":"R15-20250730","first-page":"83","article-title":"Structure and function of respiratory syncytial virus surface glycoproteins","volume":"372","author":"McLellan","year":"2013","journal-title":"Curr Top Microbiol Immunol"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/oxfordjournals.aje.a120955","article-title":"Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine","volume":"89","author":"Kim","year":"1969","journal-title":"Am J Epidemiol"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1084\/jem.20020781","article-title":"A role for immune complexes in enhanced respiratory syncytial virus disease","volume":"196","author":"Polack","year":"2002","journal-title":"J Exp Med"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"34108","DOI":"10.1038\/srep34108","article-title":"Prefusion F is absent on the surface of formalin-inactivated respiratory syncytial virus","volume":"6","author":"Killikelly","year":"2016","journal-title":"Sci Rep"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"eabj7843","DOI":"10.1126\/scitranslmed.abj7843","article-title":"Fatal enhanced respiratory syncytial virus disease in toddlers","volume":"13","author":"Polack","year":"2021","journal-title":"Sci Transl Med"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"482","DOI":"10.4161\/hv.6.6.11562","article-title":"New insights for development of a safe and protective RSV vaccine","volume":"6","author":"Blanco","year":"2010","journal-title":"Hum Vaccin"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fimmu.2014.00466","article-title":"Immunity to RSV in early-life","volume":"5","author":"Lambert","year":"2014","journal-title":"Front Immunol"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"826666","DOI":"10.3389\/fimmu.2022.826666","article-title":"Effect of infant RSV infection on memory T cell responses at age 2-3 years","volume":"13","author":"Chirkova","year":"2022","journal-title":"Front Immunol"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1128\/CMR.00090-16","article-title":"The human immune response to respiratory syncytial virus infection","volume":"30","author":"Russell","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1128\/CMR.12.2.298","article-title":"Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment","volume":"12","author":"Domachowske","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2216480","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"388","author":"Kampmann","year":"2023","journal-title":"N Engl J Med"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/infdis\/jiad024","article-title":"Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial","volume":"228","author":"Bebia","year":"2023","journal-title":"J Infect Dis"},{"key":"R30-20250730","first-page":"1053","article-title":"Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants","volume":"389","author":"Kampmann","year":"2023","journal-title":"Reply N Engl J Med"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1093\/infdis\/jiab505","article-title":"Safety and immunogenicity of a respiratory syncytial virus prefusion F vaccine when coadministered with a tetanus, diphtheria, and acellular pertussis vaccine","volume":"225","author":"Peterson","year":"2022","journal-title":"J Infect Dis"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"e50852","DOI":"10.1371\/journal.pone.0050852","article-title":"Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats","volume":"7","author":"Smith","year":"2012","journal-title":"PLoS One"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/fvl-2020-0174","article-title":"Nanoparticle vaccines against respiratory syncytial virus","volume":"15","author":"Stephens","year":"2020","journal-title":"Future Virol"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/infdis\/jiz390","article-title":"Safety and immunogenicity of a respiratory syncytial virus fusion (F) protein nanoparticle vaccine in healthy third-trimester pregnant women and their infants","volume":"220","author":"Munoz","year":"2019","journal-title":"J Infect Dis"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1908380","article-title":"Respiratory syncytial virus vaccination during pregnancy and effects in infants","volume":"383","author":"Madhi","year":"2020","journal-title":"N Engl J Med"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"1025341","DOI":"10.3389\/fimmu.2022.1025341","article-title":"Prior respiratory syncytial virus infection reduces vaccine-mediated Th2-skewed immunity, but retains enhanced RSV F-specific CD8\u200aT cell responses elicited by a Th1-skewing vaccine formulation","volume":"13","author":"Eichinger","year":"2022","journal-title":"Front Immunol"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/CVI.00609-15","article-title":"Brief history and characterization of enhanced respiratory syncytial virus disease","volume":"23","author":"Acosta","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"R38-20250730","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"issue":"(Suppl 2)","key":"R40-20250730","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1093\/infdis\/jiac216","article-title":"Expected impact of universal immunization with nirsevimab against RSV-related outcomes and costs among all US infants in their first RSV season: a static model","volume":"226","author":"Kieffer","year":"2022","journal-title":"J Infect Dis"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"e230023","DOI":"10.1001\/jamanetworkopen.2023.0023","article-title":"Monoclonal antibody for the prevention of respiratory syncytial virus in infants and children: a systematic review and network meta-analysis","volume":"6","author":"Sun","year":"2023","journal-title":"JAMA Netw Open"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s12325-022-02256-5","article-title":"Ribavirin for treatment of subjects with respiratory syncytial virus-related infection: a systematic review and meta-analysis","volume":"39","author":"Tejada","year":"2022","journal-title":"Adv Ther"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1021\/acs.jmedchem.9b00654","article-title":"Discovery of ziresovir as a potent, selective, and orally bioavailable respiratory syncytial virus fusion protein inhibitor","volume":"62","author":"Zheng","year":"2019","journal-title":"J Med Chem"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"e13176","DOI":"10.1111\/irv.13176","article-title":"Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: a phase 2 proof-of-concept trial","volume":"17","author":"Huang","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"e1009428","DOI":"10.1371\/journal.ppat.1009428","article-title":"EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a nonhuman primate model","volume":"17","author":"Rhodin","year":"2021","journal-title":"PLoS Pathog"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMoa2108903","article-title":"EDP-938, a respiratory syncytial virus inhibitor, in a human virus challenge","volume":"386","author":"Ahmad","year":"2022","journal-title":"N Engl J Med"},{"key":"R47-20250730","first-page":"420","article-title":"Respiratory syncytial virus vaccination recommendations and other updates from ACIP","volume":"108","author":"Rockwell","year":"2023","journal-title":"Am Fam Physician"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1164\/rccm.201609-1812OC","article-title":"Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing. Six-year follow-up study","volume":"196","author":"Mochizuki","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"R49-20250730","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jaci.2008.10.043","article-title":"Respiratory syncytial virus neutralizing antibodies in cord blood, respiratory syncytial virus hospitalization, and recurrent wheeze","volume":"123","author":"Stensballe","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"R50-20250730","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/infdis\/jiz408","article-title":"Safety and immunogenicity of the respiratory syncytial virus vaccine RSV\/DeltaNS2\/Delta1313\/I1314L in RSV-seronegative children","volume":"222","author":"Karron","year":"2020","journal-title":"J Infect Dis"},{"key":"R51-20250730","article-title":"Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV\/6120\/DeltaNS2\/1030\u200as in RSV-seronegative young children","author":"Karron","year":"2023","journal-title":"J Infect Dis"},{"key":"R52-20250730","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/infdis\/jiac253","article-title":"Evaluation of recombinant live-attenuated respiratory syncytial virus (RSV) vaccines RSV\/DeltaNS2\/Delta1313\/I1314L and RSV\/276 in RSV-seronegative children","volume":"226","author":"Cunningham","year":"2022","journal-title":"J Infect Dis"},{"key":"R53-20250730","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/infdis\/jiz603","article-title":"Live respiratory syncytial virus attenuated by M2-2 deletion and stabilized temperature sensitivity mutation 1030\u200as is a promising vaccine candidate in children","volume":"221","author":"McFarland","year":"2020","journal-title":"J Infect Dis"},{"key":"R54-20250730","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/infdis\/jiac407","article-title":"Phase 1\/2a safety and immunogenicity of an adenovirus 26 vector respiratory syncytial virus (RSV) vaccine encoding prefusion F in adults 18-50 years and RSV-seropositive children 12-24 months","volume":"227","author":"Stuart","year":"2022","journal-title":"J Infect Dis"},{"key":"R55-20250730","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","article-title":"Advances in respiratory virus therapeutics - a meeting report from the 6th isirv Antiviral Group conference","volume":"167","author":"Beigel","year":"2019","journal-title":"Antiviral Res"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:02:35Z","timestamp":1753898555000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001336","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]}}}